Substance / Medication

Azelastine

Overview

Active Ingredient
azelastine
RxNorm CUI
18603

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Intranasal Azelastine and Fluticasone as Combination Therapy for Allergic Rhinitis: Systematic Review and Meta-analysis.
Debbaneh Peter M, Bareiss Anna K, Wise Sarah K et al. · Otolaryngol Head Neck Surg · 2019
PMID: 30961435Meta-Analysis
The efficiency of azelastine hydrochloride and fluticasone propionate nasal spray to improve PAP adherence in patients with obstructive sleep apnea.
Wongchan Rachata, Tepwimonpetkun Chatkarin, Kitsongsermthon Jutarat et al. · Sci Rep · 2025
PMID: 40287492RCTFull text (PMC)
Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial.
Lehr Thorsten, Meiser Peter, Selzer Dominik et al. · JAMA Intern Med · 2025
PMID: 40892398RCTFull text (PMC)
Determination of the Bioavailability of 3 Intranasal Formulations of Azelastine Hydrochloride in Healthy Male Volunteers.
Bousquet Jean, Klimek Ludger, Liu Mark et al. · Clin Pharmacol Drug Dev · 2025
PMID: 39789734RCT
Onset of efficacy of azelastine hydrochloride 0.15% nasal spray for allergic rhinitis in an environmental exposure chamber.
Hsu Shu-Ning, Sajjad Fatima, Brigham Elizabeth et al. · Ann Allergy Asthma Immunol · 2024
PMID: 39067509RCT
Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients.
Klussmann Jens Peter, Grosheva Maria, Meiser Peter et al. · Sci Rep · 2023
PMID: 37100830RCTFull text (PMC)
A Comparative Study of Montelukast and Azelastine add on Therapy in Moderate to Severe Allergic Rhinitis Treatment: A Double-Blind Randomized Clinical Trial.
Esmaeilzadeh Hossein, Far Nasrin Mortazavi, Nabavizadeh Seyed Hesamedin et al. · Am J Rhinol Allergy · 2022
PMID: 35300506RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Azelastine (substance)
SNOMED CT
372520005
UMLS CUI
C0052762
RxNorm CUI
18603

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.